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COMMENTARY
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ABSTRACT
The NIH-funded center for autophagy research named Autophagy, Inflammation, and Metabolism
(AIM) Center of Biomedical Research Excellence, located at the University of New Mexico Health
Science Center is now completing its second year as a working center with a mission to promote
autophagy research locally, nationally, and internationally. The center has thus far supported a cadre
of 6 junior faculty (mentored PIs; mPIs) at a near-R01 level of funding. Two mPIs have graduated by
obtaining their independent R01 funding and 3 of the remaining 4 have won significant funding
from NIH in the form of R21 and R56 awards. The first year and a half of setting up the center has
been punctuated by completion of renovations and acquisition and upgrades for equipment sup-
porting autophagy, inflammation and metabolism studies. The scientific cores usage, and the growth
of new studies is promoted through pilot grants and several types of enablement initiatives. The
intent to cultivate AIM as a scholarly hub for autophagy and related studies is manifested in its
Vibrant Campus Initiative, and the Tuesday AIM Seminar series, as well as by hosting a major scientific
event, the 2019 AIM symposium, with nearly one third of the faculty from the International Council of
Affiliate Members being present and leading sessions, giving talks, and conducting workshop
activities. These and other events are often videostreamed for a worldwide scientific audience, and
information about events at AIM and elsewhere are disseminated on Twitter and can be followed on
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the AIM web site. AIM intends to invigorate research on overlapping areas between autophagy,
inflammation and metabolism with a number of new initiatives to promote metabolomic research.
With the turnover of mPIs as they obtain their independent funding, new junior faculty are recruited
and appointed as mPIs. All these activities are in keeping with AIM’s intention to enable the next
generation of autophagy researchers and help anchor, disseminate, and convey the depth and
excitement of the autophagy field.
Introduction
In 2017, the National Institutes of Health (NIH) funded a new
center for autophagy research, named Autophagy Inflammation
andMetabolism (AIM) Center of Biomedical Research Excellence
(CoBRE) through its research capacity building program. The
mission of the CoBRE program is to develop research infrastruc-
ture through several mechanisms housed within thematic centers,
each focused on a multidisciplinary theme. Autophagy, and its
intersections with inflammatory and metabolic processes is an
ideal multidisciplinary theme with cross-cutting implications for
both fundamental science and translational research. The AIM
center’s specific intent is to provide a regional, national and inter-
national hub for the advancement of autophagy research. This
includes autophagy as a standalone process and its intersections
with other processes, often in a disease context. AIM encourages
fundamental discoveries while cultivating connections with trans-
lationally oriented programs and research centers. The intent of
this article is to report to the autophagy scientific community the
progressmadewithin the nearly 2 years of the existence of theAIM
center, and to invite and welcome participation of all those
interested.
AIM community of scholars starts with investment in
junior faculty
The centerpiece of AIM, supported by the majority of funds
coming to the AIM center through the CoBRE P20 mechanism,
are the mentored faculty, also referred to as mentored principal
investigators (mPIs). So far, 6 mPIs and their projects have been
funded by AIM (Figure 1A) at a near-R01 level through this
mechanism. One mPI obtained an independent R01 and gradu-
ated. This PI has been recruited to Penn State, but remains
connected to AIM, as evidenced by continued interactions and
acknowledgement of the P20 grant in publications. After this
mPI’s graduation, AIM issued a Request for Applications (RFA)
to appoint a new mPI, following standard operating procedures
(SOPs) codifying admissions, progress assessment and graduation
policies by AIM. This was a competitive process with several
qualified applicants applying. Applications for mPIs include a 12-
page R01-style research proposal plus a specific aims page, along
with the biosketches for the candidate mPI and his/her mentor
plus letters of support, usually from the chair of the home or
hiring department. After external review that follows the NIH
style assessment (but without going to an NIH study section for
peer review), scores are tallied and the top candidate is approved
by AIM’s Executive Committee (EC), External Advisory Board,
and NIH program administrators.
Another mPI from the original cohort graduated upon receiv-
ing her R01 funding. In this case, the mPI stayed at the institution
and has been appointed to the EC to bring the perspective of an
mPI who recently graduated as well as becoming a co-director of
one of the scientific cores – Inflammation and Metabolism Core
(ICM) – due to extensive experience with metabolism studies and
the AIM leadership’s intent to boost metabolism research at the
center. Following the SOPs, AIM has appointed a second new
mPI. The current ‘quartet’ of mPIs study autophagy in antiviral
immunity, aging, neurological/psychiatric disorders, and T cell
biology. Three of the 4 current mPIs have obtained new NIH
funding consisting of 2 R21 awards and 1 R56 award. FuturemPIs
may also be recruited externally as new hires to UNM in colla-
boration with individual departments
Mentoring junior faculty
AIM provides mentoring to mPIs in several ways. Each mPI is
matched with a seasoned R01-funded senior faculty member
who acts as a mentor. Mentors’ salaries are in part supported
by AIM corresponding to a time commitment of approxi-
mately 3 h per week. As one of mentoring enrichment pro-
grams, AIM provides small Mentor Engagement Grants
(MEGs) to mentors. The purpose of MEGs is to increase
interest within the mentor’s laboratory in the work by the
mentee and enhance the quality of scientific interactions and
output of each mentor-mentee teem. Mentors are also mem-
bers of the Mentoring Assessment Committee (MAC), which
includes the Mentoring Director, departmental chairs of
junior faculty, and additional invited experienced faculty.
MAC assesses each mPI’s progress in a formal way twice
a year, with memoranda summarizing status and recommen-
dations. Among monitored general criteria are progress in
publications, grant applications and attendance of or presen-
tations at conferences. Each mPI develops and adheres to an
individual development plan (IDP). IDPs are custom tailored
to each mPI through initial questionnaires and are meant to
identify systematic needs for any existing training gaps or
special interests. AIM leadership is cognizant of the potential
to over-mentor, and AIM’s mentoring team and EC carefully
monitor and balance mentoring activities.
Vibrant campus initiative
The AIM center has a portfolio of evolving scholarly initia-
tives including AIM Symposia, Tuesday AIM Seminars
(TAIMS), Visiting Scholars Program (present visiting scholars
are from Norway and Brazil), various enablement activities
such as the above mentioned MEGs, and disseminating infor-
mation via the AIM web site (https://www.autophagy.center/)
on international scientific output in the field of autophagy
research. TAIMS meetings commonly include 2 talks of
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20 min maximum each, fashioned after Keystone Symposia or
Gordon Research Conference plenary presentations, followed
by brief receptions in the newly renovated AIM conference
room. These sessions are designed to showcase research activ-
ities as well as to promote informal interactions.
2019 AIM symposium
At the top of the initiatives promoting autophagy science and
vibrant scholarly environment for all AIM members and their
trainees are the annual AIM scientific symposia. After the success
of the 2018 AIM symposium, the more ambitious 2019 AIM
symposium (Figure 2; https://www.autophagy.center/node/369)
took place at the AIM center in Albuquerque, New Mexico,
USA immediately following the 2019 Keystone Symposium in
Santa Fe, the nearby state capital of NewMexico. The symposium
was organized by Dr. Vojo Deretic (The AIM Center, USA),
Dr. Leon Murphy (Casma Therapeutics, USA), and Dr. Li Yu
(Tsinghua University, China).
The first session of the 2019 AIM symposium was chaired by
Dr. Tamotsu Yoshimori, Osaka University, Osaka, Japan. It con-
sisted of plenary talks on fundamentals of autophagy: Dr Sharon
Tooze, The Francis Crick Institute, London, UK, spoke on
‘Initiation of autophagy by ATG9 vesicles and PI4P’; Dr Fulvio
Reggiori, University Medical Center Groningen, Netherlands
spoke on ‘Supplying lipids to the forming autophagosome’;
Dr Zvulun Elazar, Weizmann Institute of Science, Israel, spoke
on ‘Relationship between fatty acid, lipid synthesis and
Autophagy’.
The second session was chaired by Dr. Noboru Mizushima,
University of Tokyo, Japan. It was on ‘Autophagy Intersections
with other Pathways’, with plenary talks by Dr. Patrice
Codogno, Université Paris Descartes Sorbonne, Paris, France
who spoke on ‘Autophagy: a protective response to shear stress’;
Dr. Gábor Juhász, Institute of Genetics, Biological Research
Centre, Hungarian Academy of Sciences spoke on the
‘Intersections and different regulation of autophagy and crino-
phagy’; Dr. Thierry Galli, Institute of Psychiatry and
Neurosciences of Paris, INSERM spoke on the ‘Role of VAMP7-
dependent unconventional secretion in neurite growth’; and
Dr. Phyllis Hanson, University of Michigan, Ann Arbor
Michigan, USA spoke on ‘ESCRTs in endolysosomal membrane
repair’.
Figure 1. Summary of AIM progress, pilot and enablement programs, and membership. (A) Table of mentored PI’s status: graduations, new appointments, and NIH
grants received. (B) A sampling of pilot grant programs and enablement funds provided by the AIM center. (C) AIM membership, levels, and functions.
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The third session on Autophagy in Models for Basic Science
and Disease was chaired by Dr. Terje Johansen, The Arctic
University of Norway, Tromsø, Norway. The plenary talks were
by Dr. David Rubinsztein, Cambridge University, UK whose talk
was entitled ‘Contact inhibition compromises autophagy’;
Dr. Devrim Gozuacik, Sabanci University, Istanbul, Turkey, who
spoke on ‘Novel regulators of autophagy’; and Dr. Quan Chen,
Chinese Academy of Sciences, Beijing, China, who spoke on
‘Molecular regulation of selectivemitophagy and its role in inflam-
masome activation and hepatocarcinogenesis’.
In addition to the plenary talks, there was a workshop
session covering a plethora of autophagy research topics and
technical approaches, presented by some of the best experts in
the world. This included: Dr. Christian Behrends, Ludwig
Maximilian University of Munich, München, Germany who
covered ‘Proteomics and autophagy network regulation’;
Dr. Eeva-Liisa Eskelinen, University of Turku, Finland who
covered ‘EM/autophagasome, autophagosomal ultrastructure’;
Dr. Terje Johansen, who covered ‘Selective autophagy’;
Dr. Noboru Mizushima who covered ‘Autophagy initiation
and maturation’; Dr. Michael Ragusa, Dartmouth University,
New Hampshire, USA, who covered ‘Structural biology of
autophagy systems’; Dr. Kevin Ryan, Cancer Research,
Beatson Institute, Glasgow, UK, who covered ‘Autophagy
and cancer’; Dr. Maria Vaccaro, University of Buenos Aires,
Argentina, who covered ‘Membrane proteins and autophagy’;
and Dr. Tamotsu Yoshimori, Osaka University, Osaka, Japan
who covered ‘Autophagy in diseases’. Finally, AIM capabilities
and core facilities were covered by Drs. Judy Cannon, Yuexi
Gu, Larry Sklar, and John Weaver of the AIM center.
The symposium finished with a reception where local and
international attendees could interact with the speakers and work-
shop leaders.
Plans for third year
The plans for AIM in year 3 remain as originally proposed,
with several enhancements and special points of emphasis.
The AIM center is planning ahead on positioning itself for
long-term success, which includes a renewal after the comple-
tion of phase I (first 5 years) and application for continuation/
transition into phase II.
One of the goals for AIM is to promote metabolism
research. AIM includes 2 separate scientific cores:
Autophagy core (AC) and Inflammation and Metabolism
Core (IMC). Whereas AC has been developed in the first
2 years of the AIM center’s becoming established, the AIM
leadership has intentions to enhance IMC operations and
promote metabolomics studies by providing a pipeline and
workflow as well as financial support for outsourced metabo-
lomics analyses. Several small but adequate grants sufficient to
support pilot studies by AIM members will be provided to
carry out initial metabolomics studies and spur metabolism
research. This complements the Seahorse capabilities of the
existing AIM instruments in the IMC facility.
Whereas the AIM center is doing well, the AIM leader-
ship, with the concurrence of the External Advisory Board,
has identified several areas of emphasis where opportu-
nities for improvement exist, including increasing total
publication output, which includes not just mPIs but also
senior faculty, hosting technological workshops and open-
house events, external searches for recruitment of faculty,
career stage-adjusted mPI graduations, etc. AIM intends to
graduate one more mPI and recruit new junior faculty
into the AIM center within the next year. Additional
plans include interactions with other IDeA programs and
CoBRE centers. AIM also invites and appoints new mem-
bers, at various levels following defined admission criteria
and procedures. The membership brings benefits and
access as shown in Figure 1C. The essence of being an
AIM member has been described at length in a previous
editorial on AIM [1].
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